339 related articles for article (PubMed ID: 27821809)
21. Sensitizing TRAIL response via differential modulation of anti- and pro-apoptotic factors by AZD5582 combined with ER nanosomal TRAIL in neuroblastoma.
Huang C; He Y; Sun J; Yuan Q; Li S; Hou H; Su K; Ke C; Du Z; Yuan Z
Acta Histochem; 2022 Feb; 124(2):151856. PubMed ID: 35077998
[TBL] [Abstract][Full Text] [Related]
22. Doxorubicin-Induced TrkAIII Activation: A Selection Mechanism for Resistant Dormant Neuroblastoma Cells.
Cappabianca L; Sebastiano M; Ruggieri M; Sbaffone M; Zelli V; Farina AR; Mackay AR
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142807
[TBL] [Abstract][Full Text] [Related]
23. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Rosato RR; Almenara JA; Coe S; Grant S
Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
[TBL] [Abstract][Full Text] [Related]
24. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
[TBL] [Abstract][Full Text] [Related]
25. Actinomycin D enhances TRAIL-induced caspase-dependent and -independent apoptosis in SH-SY5Y neuroblastoma cells.
Wang MJ; Liu S; Liu Y; Zheng D
Neurosci Res; 2007 Sep; 59(1):40-6. PubMed ID: 17707539
[TBL] [Abstract][Full Text] [Related]
26. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells.
Azijli K; Yuvaraj S; Peppelenbosch MP; Würdinger T; Dekker H; Joore J; van Dijk E; Quax WJ; Peters GJ; de Jong S; Kruyt FA
J Cell Sci; 2012 Oct; 125(Pt 19):4651-61. PubMed ID: 22797920
[TBL] [Abstract][Full Text] [Related]
27. Understanding of tolerance in TRAIL-induced apoptosis and cancelation of its machinery by α-mangostin, a xanthone derivative.
Kumazaki M; Shinohara H; Taniguchi K; Ueda H; Nishi M; Ryo A; Akao Y
Oncotarget; 2015 Sep; 6(28):25828-42. PubMed ID: 26304927
[TBL] [Abstract][Full Text] [Related]
28. Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma.
Opel D; Naumann I; Schneider M; Bertele D; Debatin KM; Fulda S
Clin Cancer Res; 2011 May; 17(10):3233-47. PubMed ID: 21355080
[TBL] [Abstract][Full Text] [Related]
29. Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells.
Eggert A; Ikegaki N; Liu X; Chou TT; Lee VM; Trojanowski JQ; Brodeur GM
Oncogene; 2000 Apr; 19(16):2043-51. PubMed ID: 10803465
[TBL] [Abstract][Full Text] [Related]
30. Fenretinide-induced caspase-8 activation and apoptosis in an established model of metastatic neuroblastoma.
Raguénez G; Mühlethaler-Mottet A; Meier R; Duros C; Bénard J; Gross N
BMC Cancer; 2009 Mar; 9():97. PubMed ID: 19331667
[TBL] [Abstract][Full Text] [Related]
31. Death receptor 5 is activated by fucosylation in colon cancer cells.
Zhang B; van Roosmalen IAM; Reis CR; Setroikromo R; Quax WJ
FEBS J; 2019 Feb; 286(3):555-571. PubMed ID: 30589515
[TBL] [Abstract][Full Text] [Related]
32. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression.
Eggert A; Grotzer MA; Zuzak TJ; Wiewrodt BR; Ho R; Ikegaki N; Brodeur GM
Cancer Res; 2001 Feb; 61(4):1314-9. PubMed ID: 11245427
[TBL] [Abstract][Full Text] [Related]
33. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
34. Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway.
Chen Z; Sangwan V; Banerjee S; Chugh R; Dudeja V; Vickers SM; Saluja AK
Cancer Lett; 2014 Jun; 348(1-2):156-66. PubMed ID: 24662747
[TBL] [Abstract][Full Text] [Related]
35. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors.
Shenoy K; Wu Y; Pervaiz S
Cancer Res; 2009 Mar; 69(5):1941-50. PubMed ID: 19223550
[TBL] [Abstract][Full Text] [Related]
36. Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma.
Azuhata T; Scott D; Griffith TS; Miller M; Sandler AD
J Pediatr Surg; 2006 Aug; 41(8):1431-40. PubMed ID: 16863850
[TBL] [Abstract][Full Text] [Related]
37. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
38. Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL.
Johnsen JI; Pettersen I; Ponthan F; Sveinbjørnsson B; Flaegstad T; Kogner P
Int J Oncol; 2004 Dec; 25(6):1849-57. PubMed ID: 15547726
[TBL] [Abstract][Full Text] [Related]
39. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.
Hassanzadeh A; Farshdousti Hagh M; Alivand MR; Akbari AAM; Shams Asenjan K; Saraei R; Solali S
J Cell Physiol; 2018 Oct; 233(10):6470-6485. PubMed ID: 29741767
[TBL] [Abstract][Full Text] [Related]
40. Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2.
Wu X; Shi J; Wu Y; Tao Y; Hou J; Meng X; Hu X; Han Y; Jiang W; Tang S; Zangari M; Tricot G; Zhan F
Cancer Biol Ther; 2010 Dec; 10(11):1201-14. PubMed ID: 20953137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]